Selecting the right drug target and developing biomarkers that demonstrate drug effects on signalling pathway modulation and disease activity are important steps on the path to developing a new disease therapy.
On Target Biomarker Consulting (OTBC) is an independent specialist consultancy providing strategic and technical advice and expertise to support clients engaged in the discovery and validation
of
drug targets
and biomarkers
for respiratory diseases
and their translation
to early phase clinical studies.
With over 22 years experience
in drug discovery
for
respiratory diseases, from
drug target identification
through to
biomarker development
for early phase clinical studies, OTBC has the experience and expertise to effectively support clients on their journey from discovery to clinical translation. OTBC is experienced in helping clients leverage artificial intelligence approaches for drug target identification; progress drug assets for clinical use and; defence of drug asset IP in patent oppositions.
